Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.

The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

##STR00001##

The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

##STR00001##

The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

##STR00001##

A process for purifying a crude composition includes a monoterpene compound selected from the group consisting of monocyclic monoterpene alcohols, monocyclic monoterpene ketones, bicyclic epoxy monoterpenes and mixtures of two or more of the aforementioned compounds, such as preferably a monocyclic monoterpene alcohol. The process comprises performing a layer crystallization with a melt of the crude composition, and the melt of the crude composition subjected to the layer crystallization includes oxygen-containing solvent in a concentration of 20 ppm to 2% by weight. The oxygen-containing solvent is selected from the group consisting of water, C1-6-alcohols, C1-6-carboxylic acids, C1-6-ketones, C1-6-aldehydes, C1-12-ethers, C1-12-esters and mixtures of two or more of the aforementioned solvents.

A process for purifying a crude composition includes a monoterpene compound selected from the group consisting of monocyclic monoterpene alcohols, monocyclic monoterpene ketones, bicyclic epoxy monoterpenes and mixtures of two or more of the aforementioned compounds, such as preferably a monocyclic monoterpene alcohol. The process comprises performing a layer crystallization with a melt of the crude composition, and the melt of the crude composition subjected to the layer crystallization includes oxygen-containing solvent in a concentration of 20 ppm to 2% by weight. The oxygen-containing solvent is selected from the group consisting of water, C1-6-alcohols, C1-6-carboxylic acids, C1-6-ketones, C1-6-aldehydes, C1-12-ethers, C1-12-esters and mixtures of two or more of the aforementioned solvents.

The present invention relates to isomerizing hydroformylation of plant oils to feedstock chemicals and monomers. More particularly, the present invention relates to compound of formula (I) and process for preparation thereof using isomerizing functionalization of cashew nut shell liquid (CNSL).

##STR00001##

The present invention relates to isomerizing hydroformylation of plant oils to feedstock chemicals and monomers. More particularly, the present invention relates to compound of formula (I) and process for preparation thereof using isomerizing functionalization of cashew nut shell liquid (CNSL).

##STR00001##

According to at least one embodiment of the present description, a cement slurry includes 50% to 90% BWOC of a cement precursor material based on a total weight of the cement slurry; and from 10% to 50% BWOC of a flexible additive based on the total weight of the cement slurry. The flexible additive includes hydrophilic polyolefin fibers or 2,6-di-tert-butyl-p-cresol.

According to at least one embodiment of the present description, a cement slurry includes 50% to 90% BWOC of a cement precursor material based on a total weight of the cement slurry; and from 10% to 50% BWOC of a flexible additive based on the total weight of the cement slurry. The flexible additive includes hydrophilic polyolefin fibers or 2,6-di-tert-butyl-p-cresol.